Volume | 81,853 |
|
|||||
News | - | ||||||
Day High | 37.05 | Low High |
|||||
Day Low | 36.35 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Celldex Therapeutics Inc | CLDX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
36.74 | 36.35 | 37.05 | 37.00 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,840 | 81,853 | $ 36.83 | $ 3,015,008 | - | 22.11 - 53.18 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:04:24 | 100 | $ 37.00 | USD |
Celldex Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.06B | 55.90M | - | 6.88M | -141.43M | -2.53 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Celldex Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLDX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 38.91 | 39.67 | 35.65 | 36.76 | 534,731 | -1.91 | -4.91% |
1 Month | 40.375 | 41.67 | 35.65 | 39.03 | 618,277 | -3.38 | -8.36% |
3 Months | 37.39 | 53.18 | 35.03 | 43.43 | 952,052 | -0.39 | -1.04% |
6 Months | 22.72 | 53.18 | 22.11 | 38.01 | 889,084 | 14.28 | 62.85% |
1 Year | 31.51 | 53.18 | 22.11 | 35.69 | 676,141 | 5.49 | 17.42% |
3 Years | 30.65 | 57.20 | 19.85 | 35.74 | 627,030 | 6.35 | 20.72% |
5 Years | 3.81 | 57.20 | 1.50 | 25.00 | 662,499 | 33.19 | 871.13% |
Celldex Therapeutics Description
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. |